STOCK TITAN

Takeda Hosts Wave 1 Pipeline Market Call

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will host a conference call on April 6, 2021 to provide updates on select New Molecular Entities (NMEs) in its Wave 1 pipeline portfolio. With several NME regulatory filings expected by year-end FY2021, the company will outline plans for organic and sustainable revenue growth over the next several years.

Date
April 6, 2021

Time
8:00 a.m. – 10:30 a.m. ET / 9:00 p.m. – 11:30 p.m. JT

Agenda
The agenda for Takeda’s call is as follows:

TIME (ET)

TIME (JT)

Session/Speaker

8:00 a.m. – 8:05 a.m.

9:00 p.m. – 9:05 p.m.

Introduction
Christophe Weber, president and CEO

8:05 a.m. – 8:10 a.m.

9:05 p.m. – 9:10 p.m.

Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs

Andy Plump, president of Research and Development

8:10 a.m. – 8:35 a.m.

9:10 p.m. – 9:35 p.m.

Maribavir (TAK-620): Potential Game Changer in the Treatment for Post-Transplant Cytomegalovirus (CMV) Infection
Obi Umeh, global program lead, Rare Genetic and Hematology Therapeutic Area Unit

Claus Jepsen, head of Global Product and Launch Strategy, Rare Genetic and Hematology Therapeutic Area Unit 

8:35 a.m. – 8:40a.m.

9:35 p.m. – 9:40p.m.

Break

8:40 a.m. – 9:00 a.m.

9:40 p.m. – 10:00 p.m.

Soticlestat (TAK-935): Novel MoA for Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome

Sarah Sheikh, head of Neuroscience Therapeutic Area Unit 

Erika Gill, head of Global Product and Launch Strategy, Neuroscience Therapeutic Area 

9:00 a.m. – 9:35 a.m.

10:00 p.m. – 10:35 p.m.

Orexin Franchise Strategy Update: First Potential Medicine to Treat the Underlying Disease in Patients with Narcolepsy Type 1

Elena Koundourakis, head of Orexin Franchise Development, Neuroscience Therapeutic Area 

Erika Gill, head of Global Product and Launch Strategy, Neuroscience Therapeutic Area 

9:35 a.m. – 9:40 a.m.

10:35 p.m. – 10:40 p.m.

Delivering an Innovative Pipeline to Our Patients: Spotlight on Select Wave 1 Programs

Ramona Sequeira, president of U.S. Business Unit & Global Portfolio Commercialization 

9:40 a.m. – 10:30 a.m.

Keep reading